In our base-case analyseswe used a blend
of prices for generic and branded (market share, 9.0%), assuming
that patients using branded drugs did so for medical
reasons. Assuming generic statin prices only,we projectedthat
it would be cost-effective to treat up to 61% to 67% of adults
with statins.